Comparative Pharmacology
Head-to-head clinical analysis: DIABINESE versus GLUCOTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIABINESE versus GLUCOTROL.
DIABINESE vs GLUCOTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to cell depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor 1 (SUR1) on ATP-sensitive potassium channels, causing depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Initial: 250 mg orally once daily, increase by 125-250 mg every 1-2 weeks as needed. Maintenance: 100-500 mg once daily. Maximum: 750 mg daily.
Initial dose 5 mg orally once daily, increased by 2.5-5 mg increments weekly based on glycemic response; maximum 20 mg daily as single or divided doses (for doses >15 mg, administer in divided doses).
None Documented
None Documented
Terminal elimination half-life 25–36 hours; in renal impairment, half-life prolonged significantly.
Terminal elimination half-life: 2-4 hours (mean 3.4 hours) in normal subjects; extended up to 8-12 hours in elderly or hepatic impairment due to reduced clearance.
Primarily renal (up to 80% unchanged); minor fecal (biliary) excretion (<10%).
Primarily renal: ~80% as metabolites (mainly 4-trans-hydroxyglipizide and 3-cis-hydroxyglipizide) and ~10% unchanged; fecal: ~10%.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic